Community-acquired pneumonia
Conditions
Interventions
Experimental group:Taking Qingke Pingchuan Granule on the basis of basic treatment of western medicine.
Control group:According to "Guidelines for Diagnosis and Treatment of Adult Community-acquired Pneumonia in China (2016 Edition)", basic treatment was given to western medicine (using ß -lactam antibi
Sponsors
Jiangsu shengze hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 and < 65 years old, regardless of sex; (2) According to the "Guidelines for Diagnosis and Treatment of Adult Community-acquired Pneumonia in China (2016 Edition)", it conforms to the clinical diagnosis of community-acquired pneumonia; (3) According to the Guide of TCM Diagnosis and Treatment of Community-acquired Pneumonia (2011 Edition), TCM syndrome differentiation belongs to phlegm-heat blocking lung syndrome; (4) Severity of 4)CAP: CURB-65 score is 0-2; (5) The onset time is less than 72 hours; (6) Sign the informed consent form voluntarily, and fully understand the test content, process and possible adverse reactions.(Syndrome of phlegm-heat obstructing the lung: the main symptoms are cough, excessive phlegm, yellow phlegm, white and sticky phlegm, chest pain, red tongue, yellow and greasy tongue coating, slippery and rapid pulse. The secondary symptoms are fever, thirst, flushed face, yellow urine, dry stool and abdominal distension. )
Exclusion criteria
Exclusion criteria: (1) patients who meet the standard of severe pneumonia; (2) Complicated with other respiratory diseases, such as chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, active tuberculosis and other primary lung diseases; (3) accompanied by serious or uncontrollable underlying diseases: such as hematological diseases; Hepatic insufficiency (ALT or AST=3ULN, total bilirubin =1.5ULN), renal insufficiency (serum creatinine > 177 µ mol/L or 2mg/dL), chronic congestive heart failure (NYHA III-IV); Immunodeficiency, such as malignant tumor, organ or bone marrow transplantation, HIV infection or taking immunosuppressants in recent 3 months; (4) those who suspect or have a history of alcohol, drug abuse or mental illness; (5) Dysphagia or any history of gastrointestinal diseases affecting drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, after subtotal gastrectomy, etc.); (6) allergic constitution, or those who are known to be allergic to the ingredients of Qingke Pingchuan Granules and to basic therapeutic drugs; (7) Subjects took the study drug orally within one month before entering the group; (8) Pregnant, planned pregnancy and lactating patients; (9) According to the judgment of the researcher, there are other circumstances that are not suitable for participating in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effective rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging absorption evaluation of pneumonia;Cough score;Proportion and time of cough disappearance;Proportion and time of expectoration disappearing;Cough and expectoration assessment questionnaire;CURB-65 score;Inflammation index; | — |
Countries
China
Contacts
Public ContactSonglili
Jiangsu shengze hospital
Outcome results
None listed